Primary cultured adipocytes for gene therapy

Details Primary cultured adipocytes for gene therapy Primary cultured adipocytes for gene therapy

2008-07-17

2011-12-06

Wehbe, Anne Marie S (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C435S069100, C435S069600

Reexamination Certificate

active

08071085

ABSTRACT:
The present invention relates to primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells. This invention provides cells suitable for gene therapy, which can replace bone marrow cells and liver cells used for conventional ex vivo gene therapy. The present invention established methods for transferring foreign genes into primary cultured adipocytes, which are suitable for ex vivo gene therapy; can be easily collected and implanted; and can be removed after implantation. Specifically, the present invention established these methods that use retroviral vectors. The present invention also established primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells.

REFERENCES:
patent: 4829000 (1989-05-01), Kleinman et al.
patent: 5639275 (1997-06-01), Baetge et al.
patent: 6143530 (2000-11-01), Crouzet et al.
patent: 6153432 (2000-11-01), Halvorsen et al.
patent: 7015037 (2006-03-01), Furcht et al.
patent: 2001/0014319 (2001-08-01), Denefle et al.
patent: 2002/0076395 (2002-06-01), Crystal et al.
patent: 2002/0177551 (2002-11-01), Terman
patent: 2004/0092011 (2004-05-01), Wilkison et al.
patent: 2005/0008621 (2005-01-01), Kirkland et al.
patent: 0 237 966 (1987-09-01), None
patent: 0 237 966 (1987-09-01), None
patent: 0 281 822 (1988-09-01), None
patent: 0 281 822 (1988-09-01), None
patent: 0 326 907 (1989-08-01), None
patent: 0 394 951 (1990-10-01), None
patent: 0 493 737 (1992-07-01), None
patent: 2327224 (1999-01-01), None
patent: 11-500618 (1999-01-01), None
patent: 11-501518 (1999-02-01), None
patent: 11-127870 (1999-05-01), None
patent: 2000-514421 (2000-10-01), None
patent: 2001-521740 (2001-11-01), None
patent: WO 86/07595 (1986-12-01), None
patent: WO 87/01728 (1987-03-01), None
patent: WO 87/03885 (1987-07-01), None
patent: WO 89/04832 (1989-06-01), None
patent: WO 97/49827 (1997-12-01), None
patent: WO 97/49827 (1997-12-01), None
patent: WO99/11786 (1999-03-01), None
patent: WO99/23216 (1999-05-01), None
patent: WO99/61642 (1999-12-01), None
patent: WO 00/31267 (2000-06-01), None
patent: WO 01/11011 (2001-02-01), None
patent: WO 02/06450 (2002-01-01), None
patent: WO 2008/108344 (2008-09-01), None
Per Marin et al. (1987) Metabolism, vol. 36 (12), 1154-1160.
Herzog et al. (1999) Nat. Med., vol. 5(1), 56-63.
Roman, et al., “Circulating Human or Canine Factor IX from Retrovirally Transduced Primary Myoblasts and Established Myoblast Cell Lines Grafted into Murine Skeletal Muscle,”Somatic Cell and Molecular Genetics, vol. 18, No. 3, 1992, pp. 247-258.
Yokoyama et al., “Autologous Primary Muscle-Derived Cells Transfer into the Lower Urinary Tract,”Tissue Engineering, vol. 7, No. 4, 2001, pp. 395-404.
Feuerbach et al.; “Progress in human gene therapy”;Kidney Int.; 49(6):1791-4 (Jun. 1996).
Abraham, Judith A. et al., “Human basic fibroblast growth factor: nucleotide sequence and genomic organization,”The EMBO Journal 5(10):2523-2528 (1986).
Abumrad, Nada A. et al., “Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation,”The Journal of Biological Chemistry 268(24):17665-17668 (Aug. 25, 1993).
Arai, Tohru et al., “A new system for stringent, high-titer vesicular stomatitis virus G protein-pseudotyped retrovirus vector induction by introduction of Cre recombinase into stable prepackaging cell lines,”Journal of Virology 72(2):1115-1121 (Feb. 1998).
Bestor, Timothy J., “Gene silencing as a threat to the success of gene therapy,” 2000,J. Clin. Invest., vol. 105(4), pp. 409-411 (Feb.).
Bradley, Richard L. et al., “The adipocyte as a secretory organ: Mechanisms of vesicle transport and secretory pathways,”Recent Prog. Horm. Res. 56:329-358 (2001).
Burns, Jane C. et al, “Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells,”Proc. Natl. Acad. Sci. U.S.A. 90:8033-8037 (Sep. 1993).
Byun, J. et al., “A simple and rapid method for the determination of recombinant retrovirus titer by G418 selection,”Gene Therapy 3:1018-1020 (1996).
Cashion, L.M. et al., “Use of enhanced green fluorescent protein to optimize and quantitate infection of target cells with recombinant retroviruses,”BioTechniques 26(5):924-930 (May 1999).
Challita, Pia-Maria and Donald B. Kohn, “Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo,”Proc. Natl. Acad. Sci. U.S.A. 91:2567-2571 (Mar. 1994).
Chen, Hui et al., “Protein-tyrosine phosphatases PTP1B and Syp are modulators of insulin-stimulated translocation of GLUT4 in transfected rat adipose cells,”The Journal of Biological Chemistry 272(12):8026-8031 (Mar. 21, 1997).
Chen, Wen Yong and Tim M. Townes, “Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation,”PNAS 97(1):377-382 (Jan. 4, 2000).
Chen, Wen Yong et al., “Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase,”Proc. Natl. Acad. Sci. U.S.A. 94:5798-5803 (May 1997).
Christensen, Rikke et al., “Cutaneous gene therapy—an update,”Histochem. Cell Biol. 115(1):73-82 (Jan. 2001).
Claudio, Pier Paolo et al., “Application of the primer in situ DNA synthesis (PRINS) technique to titer recombinant virus and evaluation of the efficiency of viral transduction,”Analytical Biochemistry 291:96-101 (2001).
Dillon, Joseph S. et al., “Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor,”Endocrinology 133(4):1907-1910 (1993).
Drucker, Daniel J. et al., “Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line,”Proc. Natl. Acad. Sci. U.S.A. 84:3434-3438 (May 1987).
Drucker, Daniel J., “Biological actions and therapeutic potential of the glucagons-like peptides,”Gastroenterology 122:531-544 (2002).
Drucker, Daniel J., “Development of glucagons-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes,”Current Pharmaceutical Design 7:1399-1412 (2001).
Drucker, Daniel J., “Glucagon-like peptides,”Diabetes 47:159-169 (Feb. 1998).
Drucker, Daniel J., “Minireview: the glucagon-like peptides,”Endocrinology 142(2):521-527 (2001).
Emi, Nobuhiko et al., “Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus,”Journal of Virology 65(3):1202-1207 (Mar. 1991).
GenBank Accession No. K02729, “Mouse leukemia virus (amphotropic)”, Aug. 1, 2002 http://www.ncbi.nlm.nih.gov/entrez.
GenBank Accession No. NP—002053, “glucagon-like peptide 1 receptor [Homo sapiens]”, Apr. 23, 2005 http://www.ncbi.nlm.nih.gov/entrez.
Goto, Masaki et al., “Inhibitory effect of E3330, a novel quinine derivative able to suppress tumor necrosis factor-αgeneration, on activation of nuclear factor-κB,”Molecular Pharmacology 49:860-873 (1996).
Graziano, Michael P. et al., “Cloning and functional expression of a human glucagon-like peptide-1 receptor,”Biochemical and Biophysical Research Communications 196(1):141-146 (Oct. 15, 1993).
Groskreutz, Debyra J. et al., “Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin,”The Journal of Biological Chemistry 269(8):6241-6245 (Feb. 25, 1994).
Hauner, Hans et al., “Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium,”J. Clin. Invest. 84:1663-

Affiliated with

Also associated with

Rating

Primary cultured adipocytes for gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Primary cultured adipocytes for gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Primary cultured adipocytes for gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4296890